Glevo instruction manual

Please draw your attention to the fact that before buying the drug, you should carefully read the instructions for use, the methods of application and dosage, as well as other useful information about the drug Glevo. On the site "Encyclopaedia of Diseases" you will find all the necessary information: instructions for proper use, recommended dosage, contraindications, as well as reviews of patients who have already used this medication.

Glevo - Indications for use

Infectious-inflammatory diseases caused by microorganisms sensitive to the preparation:

- ENT organs, incl. acute sinusitis;

- lower respiratory tract, incl. exacerbation of chronic bronchitis, community-acquired pneumonia;

- urinary tract and kidney (uncomplicated and complicated infections), incl. acute pyelonephritis;

- Sexual organs, incl. prostatitis;

- skin and soft tissues (festering atheromas, abscess, furunculosis );

- intra-abdominal infections in combination with drugs acting on anaerobic microflora.

Глево - Product form

tablets, film-coated 250 mg; packing contour mesh 5 pack of cardboard 1;

tablets, film-coated 250 mg; packing contour mesh 5 pack of cardboard 5;

tablets, film-coated 500 mg; packing contour mesh 5 pack of cardboard 1;

tablets, film-coated 500 mg; packing contour mesh 5 pack of cardboard 5;

Glevo - Composition

Tablets covered with a film membrane 1 tab.

levofloxacin (as hemihydrate) (250 mg) (500 mg)

auxiliary substances: MCC; starch; povidone (K-30); crospovidone; magnesium stearate; Avicel pH 101 (MCC)

membrane: hypromellose; macrogol (polyethylene glycol 6000); dibutyl phthalate; talc; titanium dioxide; dye - iron oxide red (Table 250 mg) and dyes - iron oxide red and iron oxide yellow (Table 500 mg)

in the planar cell pack 5 pcs .; in a pack of cardboard 1 or 5 packages.

Glevo - Pharmacodynamics

Glevo is an antibacterial drug of the group of fluoroquinolones of a wide spectrum of action. Levofloxacin blocks DNA-gyrase (topoisomerase II) and topoisomerase IV, disrupts supercoiling and cross-linking of DNA gaps, suppresses DNA synthesis, causes profound morphological changes in the cytoplasm, cell wall and membranes of microorganisms.

Gleu is active against aerobic Gram-positive microorganisms: Corynebacterium diphtheriae, Enterococcus spp. (including Enterococcus faecalis), Listeria monocytogenes, Staphylococcus spp. (coagulase-negative, including methicillin-sensitive / methicillin-moderately sensitive strains), Staphylococcus aureus (methicillin-sensitive strains), Staphylococcus epidermidis (methicillin-sensitive strains), Streptococcus spp. groups C and G, Streptococcus agalactiae, Streptococcus pneumoniae (penicillin-sensitive / moderately sensitive / resistant strains), Streptococcus pyogenes, Streptococcus viridans (penicillin-moderately sensitive / resistant strains); aerobic gram-negative microorganisms: Acinetobacter spp. (including Acinetobacter baumannii), Actinobacillus actinomycetemcomitans, Citrobacter freundii, Eikenella corrodens, Enterobacter spp. (including Enterobacter aerogenes, Enterobacter agglomerans, Enterobacter cloacae), Escherichia coli, Gardnerella vaginalis, Haemophilus ducreyi, Haemophilus influenzae (Ampicillin-sensitive / resistant strains), Haemophilus parainfluenzae, Helicobacter pylori, Klebsiella spp. (including Klebsiella oxytoca, Klebsiella pneumoniae), Moraxella catarrhalis (producing and non-producing β-lactamases), Morganella morganii, Neisseria gonorrhoeae (producing and non-producing penicillinase), Neisseria meningitidis, Pasteurella spp. (including Pasteurella conis, Pasteurella dagmatis, Pasteurella multocida), Proteus mirabilis, Proteus vulgaris, Providencia spp. (including Providencia rettgeri, Providencia stuartii), Pseudomonas spp. (including Pseudomonas aeruginosa), Salmonella spp., Serratia spp. (including Serratia marcescens); anaerobic microorganisms: Bacteroides fragilis, Bifidobacterium spp., Clostridium perfringens, Fusobacterium spp., Peptostreptococcus spp., Propionibacterium spp., Veilonella spp .; other microorganisms: Bartonella spp., Chlamydia pneumoniae, Chlamydia psittaci, Chlamydia trachomatis, Legionella pneumophila, Legionella spp., Mycobacterium spp. (including Mycobacterium leprae, Mycobacterium tuberculosis), Mycoplasma hominis, Mycoplasma pneumoniae, Rickettsia spp., Ureaplasma urealyticum.

Pharmacokinetics

Suction

When ingested quickly and almost completely absorbed. Food intake has little effect on the speed and completeness of absorption. Bioavailability is 99%. Tmax - 1-2 hours. When taking the drug in doses of 250 mg and 500 mg Cmax is 2.8 μg / ml and 5.2 μg / ml, respectively.

Distribution

Binding to plasma proteins - 30-40%. It penetrates well into organs and tissues (lungs, bronchial mucosa, sputum, organs of the genitourinary system, polymorphonuclear leukocytes, alveolar macrophages).

Metabolism

In the liver, a small portion of the drug is oxidized and / or deacetylated.

Excretion

Kidney clearance is 70% of the total clearance. T1 / 2 - 6-8 hours. Excreted mainly by the kidneys through glomerular filtration and tubular secretion. Less than 5% of levofloxacin is excreted as metabolites. After oral administration, about 70% of the dose is excreted in the urine unchanged for 24 hours, about 87% of the dose for 48 hours; less than 4% - with feces for 72 hours.

Glevo - Contraindications

hypersensitivity to levofloxacin and other fluoroquinolones;

epilepsy;

the defeat of the tendons during the previous treatment with quinolones;

pregnancy ;

lactation period;

children and adolescence up to 18 years.

With caution should be used: in old age (high probability of concomitant decrease in kidney function); with deficiency of glucose-6-phosphate dehydrogenase.

Glevo - Side effects

On the part of the digestive system: nausea, vomiting, diarrhea (including with blood), digestive disorders, decreased appetite, abdominal pain, pseudomembranous enterocolitis, increased activity of hepatic transaminases, hyperbilirubinemia , hepatitis, dysbiosis.

From the side of the cardiovascular system: a decrease in blood pressure, vascular collapse, tachycardia , prolongation of the QT interval; extremely rare - atrial fibrillation .

On the part of the endocrine system: hypoglycemia (increased appetite, increased sweating, trembling, nervousness).

From the side of the central nervous system and peripheral nervous system: headache , dizziness , weakness, drowsiness, insomnia, tremor, anxiety, paresthesia, fear, hallucinations, confusion, depression , movement disorders, epileptic seizures (in predisposed patients).

From the senses: visual, hearing, smell, taste and tactile sensitivity.

From the musculoskeletal system: arthralgia, muscle weakness, myalgia, tendon rupture, tendonitis , rhabdomyolysis.

From the side of the urinary system: hypercreatininaemia, interstitial nephritis, acute renal failure.

From the hemopoietic system: eosinophilia , hemolytic anemia , leukopenia , neutropenia , agranulocytosis , thrombocytopenia , pancytopenia, hemorrhages.

Allergic reactions: skin itching and hyperemia, swelling of the skin and mucous membranes, urticaria , malignant exudative erythema ( Stevens-Johnson syndrome ), toxic epidermal necrolysis ( Lyell's syndrome ), bronchospasm, suffocation, anaphylactic shock , allergic pneumonitis, vasculitis .

Other: photosensitization, asthenia, exacerbation of porphyria, persistent fever, development of superinfection.

Glevo - Method of administration and dose

Inside, 1 or 2 times a day, without chewing and drinking with a sufficient amount of liquid (from 0.5 to 1 cup), you can take before meals or between meals. Doses are determined by the nature and severity of the infection, as well as the suspected pathogen susceptibility.

Patients with normal or moderately reduced renal function (Cl creatinine> 50 mL / min) are recommended the following dosing regimen of the drug Glevo:

Sinusitis: 500 mg once a day - 10-14 days.

Exacerbation of chronic bronchitis: 250 or 500 mg once a day - 7-10 days.

Community-acquired pneumonia: 500 mg 1-2 times a day - 7-14 days.

Uncomplicated urinary tract infections: 250 mg once a day - 3 days.

Prostatitis: 500 mg once a day - 28 days.

Complicated urinary tract infections, including pyelonephritis: 250 mg once a day - 7-10 days.

Infections of the skin and soft tissues: 250-500 mg 1-2 times a day - 7-14 days.

Intra-abdominal infection: 500 mg once a day - 7-14 days (in combination with antibacterial drugs acting on anaerobic flora).

Interaction with other drugs

With simultaneous application of levofloxacin increases T1 / 2 cyclosporine.

Action Glevo reduce drugs that depress intestinal motility, sucralfate, aluminum / magnesium-containing antacid drugs and iron salts (a break between taking at least 2 hours).

With the simultaneous use of Glevo with NSAIDs, theophylline increased convulsive readiness.

With the simultaneous use of Glevo with GCS, the risk of rupture of tendons increases.

Cimetidine and drugs that block tubular secretion, slow the withdrawal of levofloxacin.

With the simultaneous use of hypoglycemic drugs with levofloxacin, hypo- and hyperglycemia may develop. Therefore, strict control of blood glucose levels is necessary.

Glevo - Special instructions for admission

Although levofloxacin is more soluble than other quinolones, patients should conduct adequate hydration of the body.

During treatment, sun and artificial UV irradiation should be avoided to avoid damage to the skin (photosensitivity).

When there are signs of tendinitis, pseudomembranous colitis, levofloxacin is immediately withdrawn and appropriate therapy is prescribed.

It should be borne in mind that the development of seizures is possible in patients with a history of brain damage (stroke, severe trauma), and the risk of hemolysis increases with insufficiency of glucose-6-phosphate dehydrogenase.

Gleck's influence on the ability to drive vehicles and manage mechanisms

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Analogues Glevo

Structural analogues for the active substance: Ivacin; Lebel; Levot; Levotech; Levoflox; Levofloxabol; Levofloxacin; Leobeg; Leflobact; Lefokcin; Matlevo; OD Levoks; Oftakwix; Remedy; Signictsef; Tavanik; Tanflomed; Flexine; Floracid; Hayleflex; Ecology; Eleflox.

Storage conditions and shelf life

In dry, the dark place at a temperature of no higher than 25 ° C not more than 24 months.

We want to pay special attention to the fact that the description of the drug Glevo is presented for informational purposes only! For more accurate and detailed information about the drug Glevo, please refer exclusively to the manufacturer's annotation! Do not self-medicate! You should definitely consult a doctor before starting the drug!